AMDL presents DR-70 prognosis data:
This article was originally published in Clinica
Executive Summary
Latest results from the Cross Cancer Institute in Edmonton, Canada, indicate a prognostic value for AMDL's DR-70 cancer marker. AMDL claims that serum levels of DR-70 predict lung cancer survival. Patients with less than 7.25 ng/ml had a median survival of 55 weeks while those with more than 12 ng/ml survived only 17 weeks.